^
CANCER:

Colon Cancer

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
MSI-H/dMMR
Colon Cancer
nivolumab + ipilimumab
Sensitive
:
A2
ESMO 2022 - 3 weeks - (New C3)
No biomarker
Colon Cancer
capecitabine
Sensitive
:
A1
No biomarker
Colon Cancer
5-fluorouracil + irinotecan
Sensitive
:
A1
No biomarker
Colon Cancer
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Colon Cancer
bevacizumab-bvzr
Resistant
:
A1
No biomarker
Colon Cancer
irinotecan
Sensitive
:
A1
No biomarker
Colon Cancer
bevacizumab-maly
Sensitive
:
A1
No biomarker
Colon Cancer
CT-P16 (bevacizumab biosimilar)
Sensitive
:
A1
MSI-H/dMMR
Colon Cancer
CAPOX
Sensitive
:
A2
MSI-H/dMMR
Colon Cancer
FOLFOX
Sensitive
:
A2
No biomarker
Colon Cancer
oxaliplatin
Sensitive
:
A2
No biomarker
Colon Cancer
CAPOX
Sensitive
:
A2
No biomarker
Colon Cancer
FOLFOX
Sensitive
:
A2
No biomarker
Colon Cancer
mFOLFOX6
Sensitive
:
A2
NTRK3 fusion
Colon Cancer
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Colon Cancer
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Colon Cancer
larotrectinib
Sensitive
:
A2
No biomarker
Colon Cancer
bevacizumab
Sensitive
:
A2
No biomarker
Colon Cancer
5-fluorouracil + oxaliplatin + leucovorin calcium
Sensitive
:
A2
No biomarker
Colon Cancer
FLOX
Resistant
:
A2
No biomarker
Colon Cancer
dostarlimab
Sensitive
:
A2
MSI-H/dMMR
Colon Cancer
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Colon Cancer
nivolumab
Sensitive
:
A2
KRAS wild-type
Colon Cancer
panitumumab
Sensitive
:
A2
NRAS wild-type
Colon Cancer
panitumumab
Sensitive
:
A2
No biomarker
Colon Cancer
FOLFIRI + ziv-aflibercept IV
Sensitive
:
A2
BRAF wild-type
Colon Cancer
cetuximab
Sensitive
:
A2
NRAS wild-type
Colon Cancer
cetuximab
Sensitive
:
A2
KRAS wild-type
Colon Cancer
cetuximab
Sensitive
:
A2
No biomarker
Colon Cancer
FOLFIRINOX
Sensitive
:
A2
No biomarker
Colon Cancer
ramucirumab
Sensitive
:
A2
BRAF wild-type
Colon Cancer
panitumumab
Sensitive
:
A2
No biomarker
Colon Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2